Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"BostonGene","sponsor":"The Weinstock Laboratory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BostonGene Announces Scientific Collaboration with Leading Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"BostonGene","sponsor":"Transgene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"BostonGene","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment of Multiregional Clear Cell Renal Cell Carcinoma Biopsies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"BostonGene","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BostonGene","sponsor":"Transgene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Transgene, NEC, and BostonGene Expand Collaboration for Phase I\/II Clinical Trial of Neoantigen Cancer Vaccine TG4050","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by BostonGene

    Menu

    BostonGene

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              BostonGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

              Details:

              The collaboration aims to focus on the advancement of the clinical development of TG4050, an individualized immunotherapy being developed for solid tumors. It is being evaluated in Phase I for the treatment of Squamous Cell Carcinoma of Head and Neck.

              Lead Product(s): TG4050

              Therapeutic Area: Oncology Product Name: TG4050

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Transgene

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Expanded Collaboration March 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BostonGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial

              Details:

              Under the collaboration, BostonGene will support the Phase I/II study of LCB84, a TROP2-directed antibody-drug conjugate (ADC), in patients with advanced cancers.

              Lead Product(s): LCB84,Anti-PD-1 Ab

              Therapeutic Area: Oncology Product Name: LCB84

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Recipient: LegoChem Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BostonGene

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment of Multiregional Clear Cell Renal Cell Carcinoma Biopsies

              Details:

              Study finds that tumor behavior specificities linked with patient responses, and the MxIF analyses identified 14 unique cellular neighborhoods in multi-region tumors that can be utilized to optimize treatment strategies for patients with ccRCC.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Washington University School of Medicine

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BostonGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials

              Details:

              Transgene’s myvac® platform brings together a series of highly innovative technologies, such as viral genome engineering, to achieve high-speed modular manufacturing of bespoke immunotherapies.

              Lead Product(s): TG4050

              Therapeutic Area: Oncology Product Name: TG4050

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Transgene

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BostonGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BostonGene Announces Scientific Collaboration with Leading Cancer Center

              Details:

              The collaboration aims to define predictors of response to PI3 kinase inhibition in relapsed/refractory T-cell lymphomas.

              Lead Product(s): Duvelisib

              Therapeutic Area: Oncology Product Name: Copiktra

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: The Weinstock Laboratory

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 04, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY